Moreover, pancreatic cancer patients with co-expression CD133 and BMI-1 (CD133+/BMI-1+) tended to have poorer outcomes than those with other expression combinations (Fig. 2D). The gene discussed is PROM1; the disease is familial pancreatic carcinoma.